Contact

YESFAL

Co-developments

Optimal Partnerships

At the heart of our success lies the synergy between Yesfal and Milltons. These two entities operate in harmony, each contributing distinct expertise to form a comprehensive solution; offering a clear sustained and fast ROI.

Research and Development

Milltons

Researches chronic complications with Northern European Universities (Denmark, Sweden and Norway).

Creates new medical protocols and/or new products.

Creates markets by mass diagnosing an underdiagnosed population.

From concept to patient

in record time

Simple three-step process:

Define an unmet need; involve patients at scale along with multiple universities in the research.

Co-create a better solution (better diagnosis, better protocols, and a finished product), again involving the patient and their physicians in the process.

Launch in as many Yesfal markets as possible.

Product case study

Enzymax Business Case

Unmet need

+Supply Shortages: Increasing global shortages of Pancreatin (digestive enzymes used for chronic digestive complications).

+Growing market: Severe increase in prevalence of chronic digestive complications requiring digestive enymes.

Unmet need

+Supply Shortages: Increasing global shortages of Pancreatin (digestive enzymes used for chronic digestive complications).

+Growing market: Severe increase in prevalence of chronic digestive complications requiring digestive enymes.

Co-Development

with Aora health

With Aora Health, we co-developed a new generation of Pancreatic Enzyme Replacement Therapy (PERT) using a double capsule (dual release) food supplement that starts its activity in the stomach. Studies have confirmed the superiority of Enzymax* compared to pancreatin.

*Vegan, compared to pork-extracted Pancreatin.

Co-Development

with Aora health

*Vegan, compared to pork-extracted Pancreatin.

In vitro studies:

• On average 280% more effective than pancreatin. • 6 times more consistent in enzymatic activity.

In-vivo studies:

• On average 80% more effective in Vivo (mainly because the digestion starts in the stomach, hours earlier than pancreatin). • 50% reduction of painful symptoms.